Fouremm

Your points are well taken and spot on.

After the BOM miss, RVX made a strategic move to identify as a Covid therapy. Pfizer and Moderna seized the opportunity and seemingly shut the door on competitors. Apabetalones' target of BD4 in pill form seems to offer a distinct advantage both in the science and cost. Financing is the dilemma. The viability of royalty sales to fund the trial and bom2 is questionable but may be the last resort. RVX's limited resources and staff make this quite a challenge. Hepa holding the IP with ~ a 40% equity position, may be the rub with a BP takeover. Interesting days ahead.

Chicagoest

p.s. RVX just reached a new all time low of .08